Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221227 · ClinicalTrials.gov registry record · Phase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
A Phase 3 study of Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 1
- Study location
NCT07221227 is a Phase 3 study of Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,200 participants, above the 166-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (623% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07221227, a Phase 3 study of Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efimosfermin alfa
Study Locations (1)
Florida
- GSK Investigational Site - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2031-12-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221227
The ClinicalTrials.gov registry entry for NCT07221227 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 166-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (623% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07221227 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07221227 about?
NCT07221227 is a clinical study titled "A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH". The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
What is the current status of trial NCT07221227?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2025-10-23. Estimated completion is 2031-12-12.
What conditions does trial NCT07221227 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT07221227?
The interventions under investigation include: Placebo (DRUG), Efimosfermin alfa (DRUG).
Who is sponsoring clinical trial NCT07221227?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221227 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
ACTIVE NOT RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.